Missed GME or NVDA? Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
LSB Stock Forecast 2025-2026
$0.93
Current Price
$18.51M
Market Cap
Buy 0
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to LSB Price Targets
N/A
To High Target of $N/A
N/A
To Median Target of $N/A
N/A
To Low Target of $N/A
LSB Price Momentum
-6.1%
1 Week Change
-17.7%
1 Month Change
-87.0%
1 Year Change
-73.1%
Year-to-Date Change
-89.2%
From 52W High of $8.60
+6.9%
From 52W Low of $0.87
📊 TOP ANALYST CALLS
Did LSB Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if YS Biopharma is one of their latest high-conviction picks.
Latest LSB Stock Price Targets & Analyst Predictions
LSB has shown a year-to-date change of -73.1% and a 1-year change of -87.0%, reflecting downward momentum over the past year. Comprehensive analyst forecasts are currently unavailable for LSB. Please refer to the price chart above for recent performance and trends.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
LSB Analyst Ratings
0
Buy
0
Hold
0
Sell
LSB Price Target Range
Low
N/A
Average
N/A
High
N/A
Current: $0.93
Latest LSB Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for LSB.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|
Lakeshore Biopharma Co. Ltd. (LSB) Competitors
The following stocks are similar to YS Biopharma based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Lakeshore Biopharma Co. Ltd. (LSB) Financial Data
Lakeshore Biopharma Co. Ltd. has a market capitalization of $18.51M with a P/E ratio of -0.2x. The company generates $79.88M in trailing twelve-month revenue with a -75.6% profit margin.
Revenue growth is +27.7% quarter-over-quarter, while maintaining an operating margin of -68.8% and return on equity of -66.0%.
Valuation Metrics
Market Cap
$18.51M
Enterprise Value
$27.39M
P/E Ratio
-0.2x
PEG Ratio
-3.9x
Price/Sales
0.0x
Growth & Margins
Revenue Growth (YoY)
+27.7%
Gross Margin
+81.9%
Operating Margin
-68.8%
Net Margin
-75.6%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+1,388.3%
Current Ratio
1.1x
Debt/Equity
72.5x
ROE
-66.0%
ROA
-13.8%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Lakeshore Biopharma Co. Ltd. (LSB) Business Model
About Lakeshore Biopharma Co. Ltd.
What They Do
Develops and manufactures biopharmaceutical products.
Business Model
Lakeshore Biopharma generates revenue through the development and commercialization of innovative therapies in oncology, immunology, and rare genetic disorders. The company invests heavily in research and clinical trials, collaborating with academic institutions to expedite the market introduction of its biopharmaceutical products.
Additional Information
The company's commitment to addressing critical healthcare gaps positions it as a key player in the global biotech industry, focusing on personalized medicine and advanced treatment options for chronic diseases. Its strategic partnerships and robust pipeline further enhance its potential for growth and innovation.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
758
CEO
Mr. Wang Xu
Country
China
IPO Year
2021
Website
www.ysbiopharm.comLakeshore Biopharma Co. Ltd. (LSB) Latest News & Analysis
Latest News
Quick Summary
LakeShore Biopharma (Nasdaq: LSB) launched its YSJA™ rabies vaccine with a new needle-free reconstitution technology at its annual meeting in Changsha, Hunan Province on April 18, 2025.
Why It Matters
LakeShore Biopharma's launch of innovative needle-free vaccination technology could enhance market competitiveness and drive future revenue growth, impacting stock performance positively.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
LakeShore Biopharma reported FY2025H1 revenue of RMB 371.9M (+36.2% YoY) and gross profit of RMB 307.3M (+39.1% YoY). Net income was RMB 20.6M, reversing a loss from the previous year.
Why It Matters
LakeShore Biopharma's strong revenue and profit growth, alongside reduced expenses and a shift to profitability, signal operational efficiency and potential for future value appreciation.
Source: PRNewsWire
Market Sentiment:
Neutral
LakeShore Biopharma Provides Update on Ongoing Criminal Investigation Involving Former Chairman in China
6 months ago
Quick Summary
LakeShore Biopharma (Nasdaq: LSB) reported that the Shenyang Municipal Public Security Bureau is investigating former chairman Yi Zhang for unspecified actions.
Why It Matters
The criminal investigation into LakeShore Biopharma’s former chairman raises concerns about governance and potential financial misconduct, which could negatively impact the company's stock performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
LakeShore Biopharma (Nasdaq: LSB) has regained compliance with Nasdaq's minimum bid price requirement, as confirmed in a notice received on October 21, 2024.
Why It Matters
LakeShore Biopharma's regained compliance with Nasdaq's minimum bid price requirement enhances investor confidence, potentially stabilizing its stock price and improving market perception.
Source: PRNewsWire
Market Sentiment:
Neutral
LakeShore Biopharma Granted Phase III Clinical Trial Approval to Explore Simplified Regimens for YSJA Rabies Vaccine
7 months ago
Quick Summary
LakeShore Biopharma (Nasdaq: LSB) received NMPA approval for a Phase III trial in China for its four-dose YSJA rabies vaccine, which has sold over 100M doses to date.
Why It Matters
Approval for a Phase III trial in China enhances LakeShore Biopharma's growth prospects and market presence, potentially boosting stock value and investor confidence in the company's pipeline.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
LakeShore Biopharma (Nasdaq: LSB) announced financial guidance for the first half and reaffirmed full-year guidance for FY 2025, highlighting strong execution and positive momentum.
Why It Matters
LakeShore Biopharma's financial guidance signals strong performance expectations, which may boost investor confidence and impact stock prices positively.
Source: PRNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About LSB Stock
What is Lakeshore Biopharma Co. Ltd.'s (LSB) stock forecast for 2025?
Analyst forecasts for Lakeshore Biopharma Co. Ltd. (LSB) are not currently available. The stock is trading at $0.93.
Is LSB stock a good investment in 2025?
Analyst ratings for LSB are not currently available. The stock is currently trading at $0.93. Investment decisions should be based on thorough research and your personal financial goals. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for LSB stock?
Price predictions from Wall Street analysts for LSB are not currently available. The stock is trading at $0.93.
What is Lakeshore Biopharma Co. Ltd.'s business model?
Lakeshore Biopharma generates revenue through the development and commercialization of innovative therapies in oncology, immunology, and rare genetic disorders. The company invests heavily in research and clinical trials, collaborating with academic institutions to expedite the market introduction of its biopharmaceutical products.
What is the highest forecasted price for LSB Lakeshore Biopharma Co. Ltd.?
Price targets from Wall Street analysts for LSB are not currently available. The stock is trading at $0.93.
What is the lowest forecasted price for LSB Lakeshore Biopharma Co. Ltd.?
Price targets from Wall Street analysts for LSB are not currently available. The stock is trading at $0.93.
What is the overall LSB consensus from analysts for Lakeshore Biopharma Co. Ltd.?
Analyst ratings for LSB are not currently available. The stock is trading at $0.93.
How accurate are LSB stock price projections?
Stock price projections, including those for Lakeshore Biopharma Co. Ltd., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: June 19, 2025 7:01 AM UTC